MARKET

ZVSA

ZVSA

ZyVersa Therapeutics Inc
NASDAQ
0.7899
-0.0111
-1.39%
After Hours: 0.7602 -0.0297 -3.76% 19:41 03/14 EDT
OPEN
0.7800
PREV CLOSE
0.8010
HIGH
0.8198
LOW
0.7625
VOLUME
68.57K
TURNOVER
--
52 WEEK HIGH
10.20
52 WEEK LOW
0.7625
MARKET CAP
1.98M
P/E (TTM)
-0.0113
1D
5D
1M
3M
1Y
5Y
1D
ZyVersa Highlights Data Showing IC 100's Potential In Alzheimer's Disease Treatment
NASDAQ · 3d ago
Weekly Report: what happened at ZVSA last week (0303-0307)?
Weekly Report · 5d ago
ZyVersa Therapeutics announces pricing of $2M private placement
Seeking Alpha · 03/06 13:19
ZyVersa Therapeutics prices 2.1M shares at 95c in private placement
TipRanks · 03/06 13:12
*ZyVersa Therapeutics Announces Pricing of $2.0M Private Placement Priced at the Market
Dow Jones · 03/06 13:01
ZYVERSA THERAPEUTICS, INC. ANNOUNCES PRICING OF $2.0 MILLION PRIVATE PLACEMENT PRICED AT THE MARKET
Reuters · 03/06 13:00
ZyVersa Therapeutics Highlights Promising Data for Inflammasome ASC Inhibitor IC 100 in Treating Heart Failure with Preserved Ejection Fraction and Associated Metabolic Conditions
NASDAQ · 03/05 13:00
ZyVersa Therapeutics highlights data on NLRP3 inflammasome inhibition
TipRanks · 03/05 12:55
More
About ZVSA
ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on leveraging advanced technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin or 2HBCD) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS). VAR 200’s active ingredient, 2HBCD, is comprised of seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.

Webull offers Zyversa Therapeutics Inc stock information, including NASDAQ: ZVSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZVSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZVSA stock methods without spending real money on the virtual paper trading platform.